FibroGen Financial Statements (FGEN)
|
|
|
|
Report date
|
|
|
01.03.2021 |
28.02.2022 |
04.03.2022 |
27.02.2023 |
26.02.2024 |
|
12.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
176.3 |
235.3 |
235.3 |
140.7 |
147.8 |
|
180.0 |
|
Operating Income, bln rub |
|
|
-191.9 |
-288.5 |
-288.5 |
-301.0 |
-281.8 |
|
-113.0 |
|
EBITDA, bln rub |
? |
|
-164.3 |
-274.8 |
-288.5 |
-282.8 |
-261.4 |
|
-99.9 |
|
Net profit, bln rub |
? |
|
-189.3 |
-291.0 |
-291.0 |
-295.2 |
-284.2 |
|
-121.8 |
|
|
OCF, bln rub |
? |
|
81.6 |
-82.2 |
-82.2 |
-145.9 |
-315.0 |
|
-125.9 |
|
CAPEX, bln rub |
? |
|
3.99 |
30.2 |
30.2 |
38.7 |
2.52 |
|
0.376 |
|
FCF, bln rub |
? |
|
77.6 |
-112.4 |
-112.4 |
-184.7 |
-317.5 |
|
-126.2 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
2.26 |
|
2.26 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
-1.85% |
|
|
OPEX, bln rub |
|
|
359.3 |
511.0 |
511.0 |
421.5 |
398.1 |
|
232.8 |
|
Cost of production, bln rub |
|
|
8.87 |
12.9 |
12.9 |
20.3 |
18.8 |
|
41.6 |
|
R&D, bln rub |
|
|
252.9 |
387.0 |
387.0 |
296.8 |
282.9 |
|
145.9 |
|
Interest expenses, bln rub |
|
|
2.40 |
2.15 |
2.15 |
1.44 |
15.5 |
|
21.1 |
|
|
Assets, bln rub |
|
|
826.8 |
773.8 |
773.8 |
610.1 |
423.5 |
|
264.4 |
|
Net Assets, bln rub |
? |
|
422.2 |
209.1 |
209.1 |
-21.4 |
-204.2 |
|
-201.7 |
|
Debt, bln rub |
|
|
37.7 |
99.7 |
99.7 |
89.9 |
170.5 |
|
2.00 |
|
Cash, bln rub |
|
|
686.5 |
405.2 |
405.2 |
422.0 |
235.6 |
|
131.0 |
|
Net debt, bln rub |
|
|
-648.8 |
-305.5 |
-305.5 |
-332.1 |
-65.1 |
|
-129.0 |
|
|
Ordinary share price, rub |
|
|
37.1 |
14.1 |
14.1 |
16.0 |
0.886 |
|
0.550 |
|
Number of ordinary shares, mln |
|
|
89.9 |
92.3 |
92.3 |
93.6 |
97.3 |
|
100.5 |
|
|
Market cap, bln rub |
|
|
3 333 |
1 302 |
1 302 |
1 499 |
86 |
|
55 |
|
EV, bln rub |
? |
|
2 684 |
997 |
997 |
1 167 |
21 |
|
-74 |
|
Book value, bln rub |
|
|
422 |
209 |
209 |
-21 |
-204 |
|
-202 |
|
|
EPS, rub |
? |
|
-2.11 |
-3.15 |
-3.15 |
-3.15 |
-2.92 |
|
-1.21 |
|
FCF/share, rub |
|
|
0.86 |
-1.22 |
-1.22 |
-1.97 |
-3.26 |
|
-1.26 |
|
BV/share, rub |
|
|
4.70 |
2.26 |
2.26 |
-0.23 |
-2.10 |
|
-2.01 |
|
|
EBITDA margin, % |
? |
|
-93.2% |
-116.8% |
-122.6% |
-201.0% |
-176.9% |
|
-55.5% |
|
Net margin, % |
? |
|
-107.4% |
-123.7% |
-123.7% |
-209.8% |
-192.4% |
|
-67.7% |
|
FCF yield, % |
? |
|
2.33% |
-8.63% |
-8.63% |
-12.3% |
-368.2% |
|
-228.3% |
|
ROE, % |
? |
|
-44.8% |
-139.2% |
-139.2% |
1 377% |
139.2% |
|
60.4% |
|
ROA, % |
? |
|
-22.9% |
-37.6% |
-37.6% |
-48.4% |
-67.1% |
|
-46.1% |
|
|
P/E |
? |
|
-17.6 |
-4.47 |
-4.47 |
-5.08 |
-0.30 |
|
-0.45 |
|
P/FCF |
|
|
42.9 |
-11.6 |
-11.6 |
-8.12 |
-0.27 |
|
-0.44 |
|
P/S |
? |
|
18.9 |
5.53 |
5.53 |
10.7 |
0.58 |
|
0.31 |
|
P/BV |
? |
|
7.89 |
6.23 |
6.23 |
-69.9 |
-0.42 |
|
-0.27 |
|
EV/EBITDA |
? |
|
-16.3 |
-3.63 |
-3.45 |
-4.13 |
-0.08 |
|
0.74 |
|
Debt/EBITDA |
|
|
3.95 |
1.11 |
1.06 |
1.17 |
0.25 |
|
1.29 |
|
|
R&D/CAPEX, % |
|
|
6 333% |
1 282% |
1 282% |
766.1% |
11 229% |
|
38 806% |
|
|
CAPEX/Revenue, % |
|
|
2.27% |
12.8% |
12.8% |
27.5% |
1.70% |
|
0.21% |
|
| FibroGen shareholders |
